The Comparison Of Effect Of Symbicort Turbuhaler80ug/4.5ug Combined With Anhydrous Theophylline Sustained Tablets And Symbicort Turbuhaler160ug/4.5ug In The Treatment Of Patients With Moderate Bronchial Asthma

Objective: To observe the efficacy ,safety and pharmacoeconomics of inhaled Symbicort turbuhaler (budesonide and formoterol fumarate powder) 80ug/4.5ug combined with oral Anhydrous Theophylline Sustained tablets and inhaled Symbicort Turbuhaler 160ug/4.5ug in the treatment of patients with moderate bronchial asthma and compare the curative effect.Methods: 60 patients with moderate bronchial asthma were randomly divided into A and B groups .30 cases in group A were treated with inhaled Symbicort turbuhaler 80ug/4.5ug, one inhalations,twice a day combined with oral sustained-release theophylline ,200 mg per 12 hour. 30cases in group B were treated with inhaled Symbicort turbuhaler 160ug/4.5ug, one inhalations,twice a day. Both groups were received a treatment course of 12 weeks. Furthermore,Symbicort turbuhaler could be used when symptoms were poorly controlled. The change of clinical symptoms,FEVl,FEVl%and adverse events were observed before and after treatment.Results: Both groups got remarkable improvement in clinic basic control rate, ACT scores and lung function(FEVl and FEVl%) and they show significant difference after treatment(p<0.01).But there is no difference between two groups. The two groups are similar in terms of adverse events ( P > 0. 05) .The cost of A is lower. Conclusions: The efficacy and safety of inhaled Symbicort Turbuhaler (budesonide and formoterol fumarate powder) 80ug/4.5ug combined with oral Anhydrous Theophylline Sustained tablets and inhaled Symbicort Turbuhaler 160ug/4.5ug in the treatment of patients with moderate bronchial asthma is good and similar and it show better adherence and minimal adverse effects.The group A has a better pharmacoeconomics.